Revvity RVTY Life Sciences — Reportable segment operating income (loss)

Discontinued — last reported Q3 '24

Similar metrics at other companies

STELife Sciences: — Segment operating income

$61.8M+6.4%

TMOLife Sciences Solutions — Operating Income (Loss)

$954M+14.4%

DHRLife Sciences — Operating Income (Loss)

$225M+11.9%

DCILife Sciences Segment — Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest

$6.8M+17.2%

STELife Sciences: — Operating Income (Loss), Before Adjustments

$61.8M+6.4%

ECLGlobal Healthcare And Life Sciences — Operating Income

$37.5M+21.0%

Other financials

Income statement

See full

Revenue$711.1M+7.0%

Gross profit$387.7M+3.2%

Operating income$75.9M+5.1%

Net income$40.7M-3.6%

EPS (diluted)$0.36+2.9%

Balance sheet

See full

Cash & equivalents$861.5M-24.3%

Total debt$3.9B+17.8%

Total equity$7.2B-5.9%

Total assets$12.0B-2.9%

Cash flow

See full

Operating cash flow$115.2M-10.1%

CapEx$19.8M+23.7%

Free cash flow$95.5M-14.9%

Valuation

See full

Market cap$11.16B-22.9%

Enterprise value$14.24B-13.7%

P/E46.5×-4.0×

P/S3.8×-1.4×

Profitability

See full

Gross margin48.5%—

Operating margin12.4%-1.1pp

Net margin8.3%-2.1pp

FCF margin17%-1.9pp

Returns & leverage

See full

Return on equity3.2%-0.5pp

Debt / equity0.5×+0.1×

Current ratio1.7×-1.9×

Where this comes from

Reported directly by Revvity in its filing.

Tagged under the XBRL concept pki:ReportableSegmentOperatingIncomeLoss.

The official record: Revvity’s 10-Q, filed November 6, 2024, on SEC EDGAR. View the filing →

Ask your AI about Revvity's life sciences — reportable segment operating income (loss).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Revvity's life sciences — reportable segment operating income (loss)?: Revvity (RVTY) reported life sciences — reportable segment operating income (loss) of $102.98M in Q3 2024.
How has Revvity's life sciences — reportable segment operating income (loss) changed year-over-year?: Revvity's life sciences — reportable segment operating income (loss) decreased by 9.8% year-over-year, from $114.19M to $102.98M.
What does life sciences — reportable segment operating income (loss) mean?: This is the profit or loss generated by the Life Sciences segment after deducting operating expenses such as cost of revenue, R&D, and SG&A from segment revenue. It measures the core operational efficiency and profitability of the segment before interest and taxes.